BioStem Technologies

Today, BioStem Technologies announced the public filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission, advancing our planned uplisting to the Nasdaq Stock Market.

This filing represents a significant step in our evolution as a public company and reflects our commitment to transparency, strong corporate governance, and long-term value creation. We believe operating as an SEC reporting company and pursuing a Nasdaq listing will strengthen our position in the capital markets, increase visibility, improve liquidity, and support our continued growth.

As our Chairman and CEO, Jason Matuszewski, shared, this milestone reinforces our commitment to building a company positioned for long-term success while continuing to advance our mission in regenerative medicine.

Read the full announcement here: https://hubs.ly/Q04pbBNS0

The Form 10 Registration Statement has been filed with the SEC but has not yet been declared effective. BioStem's common stock will continue trading on the OTC market under the ticker symbol BSEM unless and until a Nasdaq listing is approved.

At BioStem, you'll join one of the fastest-growing regenerative medicine companies in the industry, where technology plays a critical role in advancing patient care and supporting teams that make a real difference.

We offer:
✔ Competitive compensation
✔ 401(k) with employer match
✔ Medical benefits
✔ Generous PTO and paid holidays
✔ Professional development opportunities
✔ A collaborative, innovative culture

If you're ready to help build the future of BioStem Technologies, we'd love to hear from you.

👉 Apply today: https://hubs.ly/Q04n7J2B0